IXICO plc $1.2m contract with new global pharma customer (9990M)
20 October 2016 - 5:00PM
UK Regulatory
TIDMIXI
RNS Number : 9990M
IXICO plc
20 October 2016
20 October 2016
IXICO plc
("IXICO" or the "Company")
IXICO signs US$1.2m contract with new global pharmaceutical
customer
Endorsement of IXICO's growing expertise in the analysis of
neurodegenerative diseases and the value of its Assessa(R) platform
to pharma partners
IXICO, the brain health company, today announces that it has
signed a new contract worth US$1.2m with a top 15 global
pharmaceutical company for advanced imaging clinical trial services
in a rare neurodegenerative disease, progressive supranuclear palsy
("PSP").
The project is for a Phase IIa clinical study of patients in the
early stages of PSP to develop a first-in-class therapy that could
prevent further degeneration and will utilise IXICO's
TrialTracker(TM) and Assessa(R) digital platforms to collect and
analyse MRI data from specialist imaging centres across Europe and
North America. The study is expected to complete in 2019 with the
potential to be extended further.
This new contract is a further endorsement of the utility of the
Assessa(R) digital platform to quantify disease pathology in
regions of the brain measuring disease progression in PSP patients.
This is in line with the Company's strategy to broaden the
application of the Assessa(R) platform to support both the
development of novel therapies and the management of patients and
treatment decisions in the clinic.
Progressive Supranuclear Palsy (PSP) is a Parkinson's-like
neurological condition caused by the premature loss of nerve cells
in certain parts of the brain. Over time this leads to difficulties
with balance, movement, vision, speech and swallowing. Research
suggests around 20,000 people suffer with PSP in the US alone.
Derek Hill, Chief Executive of IXICO, commented: "This contract
win adds to our portfolio of clinical trials in PSP and validates
the differentiation of our unique TrialTracker(TM) and Assessa(R)
digital platforms with a new global pharma customer. We are pleased
with the continued progress we are making to grow and evolve
relationships within the pharmaceutical industry demonstrating our
expertise across a range of neurological indications."
For further information please contact:
IXICO plc
Derek Hill, Chief Executive Officer Tel: +44 20
Susan Lowther, Chief Financial Officer 3763 7499
Shore Capital (Nomad and Broker) Tel: +44 20
Bidhi Bhoma / Edward Mansfield 7408 4090
FTI Consulting Limited (Investor Tel: +44 20
Relations) 3727 1000
Simon Conway/Mo Noonan/Matthew
Moss
About IXICO
IXICO's innovative and proprietary digital healthcare
technologies help those involved in researching and treating
serious diseases to capture and analyse clinical data to make
rapid, informed decisions. In clinical research this includes the
phenotyping of patients, quantification of disease pathology and
measurement of patient outcomes. In clinical practice the mobile
health and digital decision support technologies aid diagnosis,
patient engagement and monitoring. IXICO is also collaborating with
partners to develop companion digital health products targeted at
improving patient outcomes.
The Company's brain health focus includes Alzheimer's disease,
Huntington's disease, multiple sclerosis, Parkinson's disease,
behavioural health, child and adolescent mental health.
More information is available on www.ixico.com
Assessa(R)
Assessa(R) is a digital decision support platform to support
diagnosis of dementia in the clinic and for the quantification of
disease pathology and stratification of patients in clinical
trials. Available in both research and CE marked medical device
versions, Assessa(R) analyses and combines multi model clinical
data (such as imaging, genetic, biomarker, demographic, cognitive
and functional information) to improve the precision of patient
stratification, differential diagnosis and predict likely disease
trajectory for an individual patient. The current medical device
provides a fully automated quantitative assessment of
neurodegeneration and white matter lesions and also includes a
disease progression model which provides a prediction of likely
disease progression. The research version of Assessa(R) quantifies
disease pathology from a broader range of data modalities and
incorporates more sophisticated machine learning and disease
modelling technologies to model the likely prognoses and disease
trajectory for an individual patient.
More information is available on www.myassessa.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
CNTKKLFFQBFXFBX
(END) Dow Jones Newswires
October 20, 2016 02:00 ET (06:00 GMT)
Ixico (LSE:IXI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ixico (LSE:IXI)
Historical Stock Chart
From Apr 2023 to Apr 2024